Gilead expects HIV revenue to grow about 12% in 2026
GILD•Gilead expects 2026 HIV revenue to grow about 12%, with Yeztugo revenue forecast at approximately $1 billion. It said third-quarter HIV sales rose 18% to $6.2 billion and projected Medicare pricing changes will reduce Biktarvy revenue by approximately $1.5 billion in 2028 versus 2027.
1. Revenue outlook
Gilead expects fiscal 2026 HIV revenue growth of about 12%, including approximately $1 billion in Yeztugo revenue. Third-quarter HIV sales rose 18% to $6.2 billion; the company expects cell therapy revenue to decline by a mid-teens percentage in 2026 and Veklury revenue to total approximately $300 million.
2. Medicare pricing
Gilead projects Medicare pricing changes will reduce Biktarvy revenue by approximately $1.5 billion in 2028 versus 2027, including spillover into other payer channels. Biktarvy’s Medicare price will be $2,600 per 30-day supply starting January 1, 2028, approximately 38% below list price.
